Cell Therapy News

The NIH awarded a $13.65 million grant to researchers at University of California, Los Angeles, to develop chimeric antigen receptor T-cell therapies for the treatment of HIV.

Fox Chase Cancer Center has established a new department of bone marrow transplant and cellular therapies.

Society for Immunotherapy of Cancer announced its 2020 fellowship and award recipients.

A 14% readmission rate after receipt of axicabtagene ciloleucel supports policies that require monitoring by a caregiver after discharge, according to results of a single-center study presented during the ASCO20 Virtual Scientific Program.

The FDA cleared an investigational new drug application for BPX-603, a chimeric antigen receptor T-cell therapy for the treatment of HER2-positive solid tumors, according to a press release from the agent’s manufacturer.

A novel chimeric antigen receptor T-cell therapy showed high response rates among patients with relapsed or refractory multiple myeloma, according to updated results of the EVOLVE trial presented during the ASCO20 Virtual Scientific Program.

NantKwest and ImmunityBio have partnered on a phase 2 trial to examine the efficacy and safety of a chemoimmunotherapy regimen for treatment of metastatic or locally advanced pancreatic cancer.

NantKwest and ImmunityBio have partnered on a phase 2 trial to examine the efficacy and safety of a chemoimmunotherapy regimen for treatment of metastatic or locally advanced pancreatic cancer.

Patients who were treated with chimeric antigen receptor T-cell therapy had increased risk for major adverse CV events, researchers found.

I’m currently browsing the abstracts for the ASCO20 Virtual Scientific Program, which — of course — will be over by the time this editorial is published.